Page Title
Drug Development Pipeline
Kinnear Pharmaceuticals
Status
DiscontinuedTherapeutic Approach
Anti-Infective
This program studied CSA-131, a synthetic compound that mimics natural compounds in the body that help fight bacterial and fungal infections. CSA-131 was studied for the potential to inhibit the growth of bacteria and fungi by breaking down their biofilms -- protective layers that bacteria and fungi form that make them more difficult to kill with anti-infectives -- and ultimately killing these organisms.
Status
No further development in CF is planned at this time.
Sponsor
This program was sponsored by Kinnear Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More